Canbridge, UMass partner on gene therapies for neuromuscular diseases

By The Science Advisory Board staff writers

September 9, 2020 -- Canbridge Pharmaceuticals has expanded its gene-therapy partnership with the University of Massachusetts (UMass) Medical School.

Under the direction of Miguel Sena-Esteves, PhD, of UMass, the second sponsored program between Canbridge and the university will focus on the development of customized adeno-associated virus (AAV) vectors with broad applications for treating neuromuscular diseases, according to the company.

The new collaboration follows an agreement earlier this year to study gene therapy-based treatments with Guangping Gao, PhD, director of UMass Medical School's Horae Gene Therapy Center.

Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of...
New gene therapy destroys latent oral herpes in mice
Researchers recently reported that they were able to eliminate latent herpes simplex virus 1 in mice using a new gene editing technique that targets the...
New CRISPR-repressor system improves efficiency of gene therapies
Researchers have developed a CRISPR-based system that can simultaneously provide transcriptional control and gene editing on demand to improve the efficacy...
Spell-check gene editing corrects hearing loss in mice
Using a new genetic engineering technique called base editing, researchers restored genetic hearing loss in mice with a recessive point mutation. The...
Scientists alter cell function with genetic engineering, polymer science
A new method called genetically targeted chemical assembly (GTCA) has demonstrated the ability to build artificial structures within the body to carry...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter